Anti-Fas

Our anti-Fas monoclonal antibody CH-11 is the original.

It induces apoptosis.


Anti-Fas monoclonal antibodies

<table>
<thead>
<tr>
<th>Code No.</th>
<th>Clone</th>
<th>Presentation</th>
<th>Volume</th>
<th>Applications</th>
</tr>
</thead>
<tbody>
<tr>
<td>SY-001</td>
<td>CH-11</td>
<td>IgM</td>
<td>50μl(1mg/ml)</td>
<td>Induction of apoptosis</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Flow cytometry</td>
</tr>
<tr>
<td>MD-10-3</td>
<td>UB2</td>
<td>IgG</td>
<td>100μl(1mg/ml)</td>
<td>Flow cytometry</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Immunohistochemistry</td>
</tr>
<tr>
<td>MD-10-4</td>
<td>UB2</td>
<td>F(ab')₂</td>
<td>50 tests</td>
<td>Flow cytometry</td>
</tr>
<tr>
<td></td>
<td></td>
<td>FITC conj.</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Specificity: React specifically with human Fas antigen. No cross-reaction with TNF receptor and mouse Fas antigen.

For research use only

MEDICAL & BIOLOGICAL LABORATORIES CO., LTD.
5-10 Marunouchi 3 chome, Naka-ku, Nagoya 460, JAPAN
TEL: (052) 971-2081 FAX: (052)971-2337

MBL International Corporation
440 Arsenal Street , Watertown, MA 02172, USA
TEL : (617) 926-6964 FAX : (617) 926-6954

PanVera Corporation
565 Science Drive, Madison, WI 53711, USA
TEL: (608) 233-9450 FAX: (608) 233-3007
Toll Free: 800-791-1400
ASSOCIATE DIRECTOR
Developmental Therapeutics Program (DTP)
Division of Cancer Treatment (DCT)
National Cancer Institute, National Institutes of Health (NIH)
Public Health Service (PHS)

The NCI is accepting applications for the position of Associate Director, DTP, located in Rockville, Maryland. We are seeking scientists experienced in biology, microbiology, pharmacology, chemistry, or medicine, who have demonstrated the ability to manage the planning, direction and implementation of a broad national and international program of drug discovery and development. The DTP is designed specifically to maintain a continuous flow of therapeutic agents and materials from laboratory clinics for the treatment of cancer and AIDS. The DTP is composed of three distinct segments with an annual funding level of approximately $134 million. The segments consist of a large extramural contract-based drug-development program (approximately $40 million), a grant-supported Biochemistry and Pharmacology program (approximately $77 million), and an intramural, laboratory oriented research program (approximately $17 million) exclusive of salaries and related fringe benefits. The DTP staff consists of approximately 225 scientific and supporting personnel.

SALARY - Ranges from $69,427 to $91,029 per annum. Physicians may be eligible for an added allowance up to $20,000 per annum.

BENEFITS - Health and life insurance options, retirement, paid holidays, vacation and sick leave.

Applicants must possess a minimally satisfactory level of competence in the knowledges, skills, and/or abilities listed below to meet minimal qualifications for the position.

1. Ability to manage laboratory or clinical research program as they relate to cancer in one or more of the following biomedical sciences: medical oncology, chemistry, biology, biochemistry, internal medicine, pharmacology.
2. Ability to direct and guide programs and projects, including long and short-term goals and priorities, and the structure necessary to carry them out.
3. Ability to obtain and allocate the financial and material resources necessary to support program or policy implementation.
4. Ability to establish and maintain effective collaborative relationships with other key scientists and groups within the U.S. and abroad having similar or related research interests.

For further qualification requirements, application procedures, and other additional information please contact Ms. Suzanne Ryan, Personnel Management Specialist, NCI at (301) 496-8657.

Applications for Federal Employment (SF-171), are to be sent to the above individual at: The National Cancer Institute, Personnel Management Branch, 6120 Executive Boulevard, Executive Plaza South, Room 531, Rockville, Maryland 20852. A current curriculum vitae and bibliography must accompany all applications for this position. However, interested Public Health Service Commissioned Officers currently within the Commissioned Corps may submit a resume in lieu of a SF-171.

Applications must be postmarked no later than the announcement closing date of August 8, 1994. To be considered, applicants must be U.S. citizens.

NIH IS AN EQUAL OPPORTUNITY EMPLOYER
ASSOCIATE DIRECTOR
Radiation Research Program (RRP)
Division of Cancer Treatment (DCT)
National Institutes of Health, National Cancer Institute (NCI)

Location: Rockville, Maryland

As Associate Director of the Radiation Research Program (RRP), the incumbent has overall responsibility for the planning, evaluation, and coordination of broad national and international radiation research programs designed to determine the effectiveness of radiation in cancer treatment, its usefulness in the diagnosis of cancer and other diseases, and the biological effects of exposures to low doses of ionizing and nonionizing radiations. Directs and manages extramural radiation research supported by the NCI’s Division of Cancer Treatment (DCT). Coordinates, reviews and implements the fiscal management of RRP’s budget which includes grants (Research Project Grants-R01, Program Project Grants-P01, Conference Grants-R13), research and resource contracts, and cooperative agreements which has an approximate operating budget of $110 million. RRP presently has a staff of 12 full time employees which includes support as well as scientific personnel.

SALARY - Ranges from $71,049 to $91,029 per annum. Physicians may be eligible for an added allowance up to $20,000 per annum.

BENEFITS - Health and life insurance options, retirement, paid holidays, vacation and sick leave.

Applicants must meet the minimum educational requirements for Medical Officer, GS-602. In addition, applicants must possess a minimally satisfactory level of competence in the knowledges, skills, and/or abilities listed below to meet minimal qualifications for the position.

1. Ability to direct, lead and manage preclinical/clinical research programs as they relate to cancer in one or more radiation specialities, e.g. radiotherapy, diagnostic imaging, nuclear medicine, radiation biology, physics.

2. Ability to plan, develop and implement research projects and programs including the formulation of program objectives and goals.

3. Ability to obtain and allocate the financial and material resources necessary to support program/policy implementation, and the ability to recruit, manage, and motivate personnel necessary to support the program.

4. Ability to establish and maintain effective collaborative relationships with other key scientists and groups within the U.S. and abroad having similar or related research interests.

For further qualification requirements, application procedures, and other additional information please contact Ms. Suzanne Ryan, Personnel Management Specialist, NCI at (301) 496-8657.

Applications for Federal Employment (SF-171), are to be sent to the above individual at: The National Cancer Institute, Personnel Management Branch, 6120 Executive Boulevard, Executive Plaza South, Room 531, Rockville, Maryland 20852. A current curriculum vitae and bibliography must accompany all applications for this position. However, Interested Public Health Service Commissioned Officers currently within the Commissioned Corps may submit a resume in lieu of a SF-171.

Applications must be postmarked no later than the announcement closing date of August 8, 1994. To be considered, applicants must be U.S. citizens.

NIH IS AN EQUAL OPPORTUNITY EMPLOYER
MEDICAL ONCOLOGISTS
Assistant/Associate Professor
Roswell Park Cancer Institute and State University of New York at Buffalo

Immediate openings exist as part of the Division of Solid Tumor Oncology and Investigational Therapeutics. Roswell Park Cancer Institute is one of the largest cancer institutes in the world and one of the nation’s 28 National Cancer Institutes designated Comprehensive Cancer Centers.

Under the direction of Derek Raghavan, M.D., Ph.D., Division Chief, multidisciplinary clinics have been developed for the management of a broad range of solid tumors, including thoracic malignancy, breast cancer, genitourinary malignancy, head and neck cancer, sarcoma/melanoma, esophageal cancer, colorectal malignancy and other upper gastrointestinal cancers. These clinics involve active participation by Medical Oncologists, Surgical Oncologists (Chair, Nicholas J. Petrelli, M.D.) and Radiation Oncologists (Chair, Kyu S. Shin M.D.) with joint patient management, multidisciplinary tumor conferences and multimodality protocols.

The research emphases of the Division of Solid Tumor Oncology include phase 1-111 assessment of new agents and treatment strategies and structured evaluation of combined modality management programs. The divisional laboratory program is focused on drug resistance and tumor cell heterogeneity and is based in our newly renovated laboratory facility. An expanded Division of Investigational Therapeutics includes extensive facilities for clinical pharmacology studies, with emphasis on new platinum complexes, platinum resistance and differentiating agents, with substantial funding from the National Institutes of Health and the pharmaceutical industry.

Successful applicants should be able to: provide consultative and attending services in Medical Oncology, undertake student and graduate teaching, and supervise resident/fellowship activities. Assistant Professor candidates must show evidence of experience in clinical care and teaching and demonstrate potential to develop an outstanding clinical or laboratory research program. Start-up funds and laboratory facilities are available for successful candidates. Associate Professor candidates must provide evidence of a strong research program as well as demonstrate substantial skill in clinical care and teaching. Candidates must be Board Certified in Internal Medicine and Board eligible or certified in Medical Oncology, as well as be able to meet medical licensure requirements in NYS. Roswell Park Cancer Institute offers a highly competitive salary and comprehensive benefits package.

Send curriculum vitae to: Clara D. Bloomfield, M.D., Chair, Department of Medicine; or Derek Raghavan, M.D., Ph.D., Chief, Division of Solid Tumor Oncology and Investigational Therapeutics, Roswell Park Cancer Institute, Elm and Carlton Streets, Buffalo, NY 14263. Roswell Park is an M/F/D/V Affirmative Action Employer.

MOLECULAR MECHANISMS OF ENVIRONMENTAL CARCINOGENESIS
September 19-20, 1994

This conference, to be held at the National Institute of Environmental Health Sciences in Research Triangle Park, North Carolina, will examine the role of onco-genes, tumor suppressor genes, cell cycle control genes, hormones/hormone receptors, and cancer susceptibility genes in the multi-step development of neoplasia and how these vital molecular targets are affected by environmental insults.

The themes are as follows:

Session I: Cell Cycle and Cancer
Session II: Cancer Susceptibility Genes
Session III: Hormones and Cancer
Session IV: Tumor Suppressor Genes

In addition, there will be a poster session on the afternoon of September 19.

For registration information please contact:
Ms. Laurie Parker
NIEHS
PO Box 12233, MD B3-07
Research Triangle Park, NC 27709-2233
(FAX) 919-541-1460

SENIOR FACULTY POSITION
Wayne State University School of Medicine seeks applicants for senior faculty position for prostate cancer research. M.D. or Ph.D. with previous expertise in prostate cancer research/administrative experience. Initial support with appropriate faculty rank, space, laboratory development and technical assistance.

Responsibilities: leadership participation in the expansion of basic prostate cancer research and recruitment of junior faculty. WSU is EEO/AAE.

Send CV to:
Gwen MacKenzie
Administrative VP
MCF-Prentis Comprehensive Cancer Center
Wayne State University
3990 John R, #104
Detroit, MI 48201

NIEHS
AACR SPECIAL CONFERENCE IN CANCER RESEARCH

Basic and Clinical Aspects of Prostate Cancer

December 8-12, 1994
Marriott's Rancho Las Palmas Resort, Rancho Mirage (Palm Springs), CA

CONFERENCE CHAIRPERSON
Donald S. Coffey / Baltimore, MD

PROGRAM COMMITTEE
Evelyn R. Barrack / Baltimore, MD  Leland W. K. Chung / Houston, TX  Gary J. Miller / Denver, CO
Howard I. Scher / New York, NY  Donald J. Tindall / Rochester, MN

CONFERENCE SPEAKERS AND SESSION CHAIRPERSONS

Evelyn R. Barrack / Baltimore, MD  *Gail Prins / Chicago, IL
Robert E. Bookstein / San Diego, CA  *David R. Rowley / Houston, TX
Maarten C. Bosland / Tuxedo, NY  *Avery A. Sandberg / Scottsdale, AZ
Otis W. Brawley / Rockville, MD  Peter T. Scardino / Houston, TX
William J. Catalona / St. Louis, MO  Jack A. Schalken / Nijmegen, The Netherlands
Leland W. K. Chung / Houston, TX  Howard I. Scher / New York, NY
*Michael Freeman / Boston, MA  William U. Shipley / Boston, MA
Norman Greenberg / Houston, TX  Jonathan W. Simons / Baltimore, MD
Stephen Harris / San Antonio, TX  Michael B. Sporn / Bethesda, MD
Warren D. W. Heston / New York, NY  *Thomas Stamey / Stanford, CA
*G. Herbst / New York, NY  *Kenneth D. Tew / Bethesda, MD
*Donald Ingber / Boston, MA  Donald J. Tindall / Philadelphia, PA
John T. Isaacs / Baltimore, MD  Timothy C. Thompson / Houston, TX
William B. Isaacs / Baltimore, MD  Donald J. Tindall / Rochester, MN
Robert B. Jenkins / Rochester, MN  Jan Trapman / Houston, TX
Aaron E. Katz / New York, NY  Alice S. Whittemore / Stanford, CA
*Chung Lee / Chicago, IL  George Wilding / Madison, WI
Hans Lilja / Malmo, Sweden  George L. Wright, Jr. / Norfolk, VA
Christopher J. Logothetis / Houston, TX  * denotes session chairperson
Jill A. Macoska / Detroit, MI  Applicants are encouraged to submit abstracts for
Timothy McDonnell / Houston, TX  poster presentation.
Wallace McKeegan / Houston, TX  Application Deadline: September 8, 1994
Charles Meyers / Charlottesville, VA  
Gary J. Miller / Denver, CO  Information and Application Forms:
William G. Nelson / Baltimore, MD  American Association for Cancer Research
Arthur B. Pardee / Boston, MA  Public Ledger Building, Suite 816
Drew M. Pardoll / Baltimore, MD  150, South Independence Mall West
Ira Pastan / Bethesda, MD  Philadelphia, PA  19106-3483
Donna M. Peetl / Stanford, CA  215-440-9300  215-440-9313 (FAX)
Kenneth J. Plenta / Detroit, MI
AACR SPECIAL CONFERENCE IN CANCER RESEARCH

Translational Research in Cancer: New Opportunities for Progress

Supported by a Generous Grant from the National Institute of Environmental Health Sciences

November 29 - December 4, 1994
The Grove Park Inn, Asheville, North Carolina

CONFERENCE CHAIRPERSON
Carlo M. Croce / Philadelphia, PA

PROGRAM COMMITTEE

Martin D. Abeloff / Baltimore, MD
Clara D. Bloomfield / Buffalo, NY
Bruce D. Cheson / Bethesda, MD
Robert L. Comis / Philadelphia, PA
Mark A. Israel / San Francisco, CA
Marc E. Lippman / Washington, DC

Keynote Address
Webster K. Cavenee / La Jolla, CA

Hematopoietic Malignancies - Biology
Max D. Cooper / Birmingham, AL
Edward A. Clark / Seattle, WA
Bice Perussi / Philadelphia, PA
Drew M. Pardoll / Baltimore, MD

Hematopoietic Malignancies - Molecular Biology
Carlo M. Croce / Philadelphia, PA
Ell Canaan / Rehovot, Israel
Stephan W. Morris / Memphis, TN

Hematopoietic Malignancies - Treatment
Albert B. Delisseroth / Houston, TX
Neal A. Flomenberg / Milwaukee, WI
Lee M. Nadler / Boston, MA
Bruce D. Cheson / Bethesda, MD
John C. Reed / La Jolla, CA
Clara D. Bloomfield / Buffalo, NY

Cytogenetics of Solid Malignancies/Sarcomas/Brain Tumors
Felix Mittelman / Lund, Sweden
Frederic G. Barr / Philadelphia, PA
Mark A. Israel / San Francisco, CA
Mark Noble / London, England

Prostate Cancer and Ovarian Cancer
John T. Isaacs / Baltimore, MD
Donald S. Coffey / Baltimore, MD
Thomas C. Hamilton / Philadelphia, PA
Robert F. Ozols / Philadelphia, PA

Lung Cancer
John D. Minna / Dallas, TX
Susan L. Hoger / San Antonio, TX
Paul A. Bunn, Jr. / Denver, CO

Breast Cancer
Marc E. Lippman / Washington, DC
Ira Pastan / Bethesda, MD
Kari Erik Hellström / Seattle, WA
Charles R. King / Philadelphia, MD
Lance A. Lottia / Bethesda, MD
Jackson B. Gibbs / West Point, PA
Martin D. Abeloff / Baltimore, MD

Colorectal Cancer
Raymond L. White / Salt Lake City, UT
Richard Flahel / Burlington, VT
Richard Kolodner / Boston, MA
Glenn Steele, Jr. / Boston, MA

Applicants are encouraged to submit abstracts for poster presentation.

Information and Application Forms
American Association for Cancer Research
Public Ledger Building, Suite 816
150 South Independence Mall West
Philadelphia, PA 19106-3483
215-440-9300 215-440-9313 (FAX)
This issue’s cover features Frederick F. Becker, Vice President for Research and Scientific Director at the University of Texas M. D. Anderson Cancer Center in Houston, TX. Dr. Becker is responsible for establishing the center as one of the major entities in research devoted to the cancer cell, cancer prevention, and experimental therapy and has guided its enormous increase in research facilities. During the last 13 years, Dr. Becker redesigned the Cancer Center’s research format, first recruiting an outstanding group of basic scientists and chairpersons. It was upon this base that the recruitment of clinician-scientists was built. He has especially fostered collaborative and translational research, has designed and supervised the construction of 500,000 feet of laboratory space, and was instrumental in developing a major endowment to support new and innovative research. As a result of his leadership, M. D. Anderson has gained much prestige and has become recognized worldwide as one of the leading cancer centers.

Dr. Becker received his B.A. degree from Columbia College in 1952, and his M.D. degree from New York University School of Medicine in 1956. During his junior and senior years in medical school, Dr. Becker had the privilege of becoming the first research fellow of the renowned biologist and biological philosopher Lewis Thomas. Dr. Becker returned to New York University School of Medicine and Bellevue Hospital after serving as a medical intern on the Harvard Service at Boston City Hospital and became one of the first resident fellows in the new program of pathology/research created by Dr. Thomas. From 1960 to 1962, he served as Deputy Director of the Pathology Department, Naval Medical Research Institute, Bethesda, MD, and then returned to New York University as Assistant Professor of Pathology. Seven years later, he was promoted to the rank of Professor of Pathology. From 1970 to 1975, he was the Director of the Department of Pathology at Bellevue Hospital Center and Acting Chairman of the Department of Pathology at New York University School of Medicine.

From 1976 to 1979, Dr. Becker served as Professor and Chairman, Department of Anatomic and Research Pathology, of the University of Texas M. D. Anderson Cancer Center. Since 1980, he has held the positions of Vice President for Research, Professor of Pathology, and Chief of the Section of Experimental Pathology. In 1988, he was also appointed as Scientific Director of the Cancer Center. In 1991, he was honored as the only research administrator at the University of Texas System to be awarded a Chair in Basic Science.

Dr. Becker’s contributions to our understanding of the mechanisms of carcinogenesis and to cancer biology have been remarkable for their quality and quantity. His early studies with George Tebor of New York University led to an understanding of the heterogeneity of alterations that are associated with chemical carcinogenesis. In collaboration with Stewart Sell, he made fundamental contributions to our understanding of the expression of fetal antigens and, in particular, a-fetoprotein, as an early manifestation of the alterations produced by carcinogens. Dr. Becker’s laboratory was the first to describe the hypomethylation of nuclear DNA isolated from premalignant and malignant liver tumors, suggesting that alterations in methylation could contribute to the malignant phenotype. Studies ranging from the effect of carcinogenic adducts and photodimers on DNA methylation to one of the first isolations of the enzyme DNA methyltransferase followed.

More recently, Dr. Becker has analyzed the biological effects of the mutant agouti alleles, which, to date, represent the most clearly identified mammalian genes related to tumor promotion. A collaboration with Peter Gascoyne of the M. D. Anderson Cancer Center and Ronald Pettig of the University of North Wales resulted in a pioneering application of a new biophysical analytical technique, dielectrophoresis, to the study of cancer cells.

Dr. Becker is the author of more than 190 research papers and 25 book chapters. He developed and edited a 6-volume work, Cancer, A Comprehensive Treatise (New York: Plenum Publishing Corp., 1975–1977), a vital source in the field that has served as a model for subsequent cancer literature. He has also developed and edited an 8-volume work called The Liver (New York: Marcel Dekker, 1974–1989) with special emphasis on basic science and the clinical research aspects of the organ’s normal and pathological states.

He has been a loyal member of and contributor to the American Association for Cancer Research since 1968. Among his honors was his selection as the Chairperson of the Gordon Conference on Cancer in 1980 and the Presidency of the American Association of Pathologists in that same year. In 1983, he was awarded the Solomon A. Berson Medical Alumni Achievement Award of New York University School of Medicine. In November 1989, Dr. Becker received the signal honor of being elected Corresponding Member of the Royal Academy of Arts and Sciences of Spain. In 1990, President George Bush appointed him as a distinguished member of the National Cancer Advisory Board.

Pictured with Dr. Becker are several key buildings that are part of the University of Texas M. D. Anderson Cancer Center and one that is to be completed in the near future. From top left: Veterinary Resources, Bastrop (1975); Smith Research Building (1980); Basic Research Building (1986); Molecular Carcinogenesis Building, Smithville (1992); and Bertner Research Building (expected completion date--1996).

We are grateful to Isaiah J. Fidler for information and photographs.

Sidney Weinhouse